Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
PhaseBio Pharmaceuticals Inc.
PHASQCurrent price
0.0001 USD
0 USD (0.00%)
Last closed
0.0001 USD
Company
–
ISIN
US7172241090
Sector
Healthcare
Industry
Biotechnology
Exchange
PINK
Capitalization
4 986 USD
Yield for 12 month
-75.00 %
1Y
3Y
5Y
10Y
15Y
PHASQ
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on June 26, 2024. Address: 1 Great Valley Parkway, Malvern, PA, United States, 19355
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1 USDP/E ratio
–Dividend Yield
–Current Year
+10 831 USD
Last Year
+320 000 USD
Current Quarter
+208 000 USD
Last Quarter
+117 000 USD
Current Year
+10 831 USD
Last Year
+320 USD
Current Quarter
+208 000 USD
Last Quarter
+117 000 USD
Key Figures PHASQ
1 year
3 years
5 years
10 years
EBITDA
-102 262 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-106.07 %
PEG Ratio
–
Return On Equity TTM
–
Wall Street Target Price
1 USD
Revenue TTM
818 000 USD
Book Value
-2.36 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-98 %
Dividend Yield
–
Gross Profit TTM
-91 276 000 USD
Earnings per share
-2.14 USD
Diluted Eps TTM
-2.14 USD
Most Recent Quarter
II 2022
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PHASQ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PHASQ
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation PHASQ
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.044
Price Sales TTM
0.0061
Enterprise Value EBITDA
0.0239
Price Book MRQ
26.18
Financials PHASQ
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PHASQ
For 52 weeks
0.0001 USD
0.001 USD
50 Day MA
0.0001 USD
Shares Short Prior Month
1 468 478
200 Day MA
0.0001 USD
Short Ratio
1.89
Shares Short
2 066 603
Short Percent
5.11 %
BeatStart